Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHARMACOECONOMICS OF THE NEW ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA
Autore:
ZITO JM;
Indirizzi:
UNIV MARYLAND,DEPT PHARM PRACTICE & SCI,SCH PHARM,100 PENN ST,SUITE 240B BALTIMORE MD 21201 UNIV MARYLAND,DEPT MED BALTIMORE MD 21201
Titolo Testata:
The Psychiatric clinics of North America
fascicolo: 1, volume: 21, anno: 1998,
pagine: 181 -
SICI:
0193-953X(1998)21:1<181:POTNAF>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC-RESISTANT SCHIZOPHRENIA; COST-EFFECTIVENESS; CLOZAPINE TREATMENT; DOUBLE-BLIND; PARALLEL-GROUP; DRUG-THERAPY; RISPERIDONE; HALOPERIDOL; MULTICENTER; REDUCTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Citazioni:
66
Recensione:
Indirizzi per estratti:
Citazione:
J.M. Zito, "PHARMACOECONOMICS OF THE NEW ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA", The Psychiatric clinics of North America, 21(1), 1998, pp. 181

Abstract

Inevitably, the greater availability of more costly antipsychotic medications has resulted in attempts to regulate the use of these agents. Early objections over the cost of treatment with clozapine or risperidone have in part been mollified by preliminary statistics on the costeffectiveness of these agents. However, this issue is complex and requires careful consideration of pharmacoeconomic principles in the development and clinical distribution of novel antipsychotics. Future cost-effectiveness studies need to consider a balance of public and private perspectives. These studies should be conducted in several settings,preferably also within the context of broader, multimodal treatment intervention strategies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 00:53:08